Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (201-210 of 391) with videos related to

Pageof 40
Sort By:
Annals of the Rheumatic Diseases|April 30, 2026
Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trialAnna-Maria Hoffmann-Vold, Shervin Assassi, Vincent Cottin, et al.
Trials|June 17, 2017
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trialPeter Saunders, Vicky Tsipouri, Gregory J Keir, et al.
American Journal of Respiratory and Critical Care Medicine|August 29, 2020
BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE StudyPhilip L Molyneaux, Jonathan J Smith, Peter Saunders, et al.
The European Respiratory Journal|July 3, 2025
Development and validation of a predictive 6-minute walk score in patients with Idiopathic Pulmonary FibrosisSteven D Nathan, Jie Gao, Ho Cheol Kim, et al.
The European Respiratory Journal|July 7, 2017
Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosisJoseph Jacob, Brian J Bartholmai, Srinivasan Rajagopalan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 20, 2012
18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trialsThida Win, Tryphon Lambrou, Brian F Hutton, et al.
ERJ Open Research|July 19, 2023
Airway soluble CSF1R predicts progression in patients with idiopathic pulmonary fibrosisJustin M Oldham, Kirk W Johnson, Gesa J Albers, et al.
Trials|March 3, 2022
PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis CoughZhe Wu, Winston Banya, Nazia Chaudhuri, et al.
Respiratory Medicine|July 23, 2013
The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung diseaseAmit S Patel, Richard J Siegert, Gregory J Keir, et al.
Clinical and Experimental Rheumatology|July 1, 2017
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)Oliver Distler, Kevin K Brown, Jörg H W Distler, et al.
Pageof 40

Showing results (201-210 of 391) with videos related to

Sort By:
Pageof 40
Annals of the Rheumatic Diseases|April 30, 2026
Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trialAnna-Maria Hoffmann-Vold, Shervin Assassi, Vincent Cottin, et al.
Trials|June 17, 2017
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trialPeter Saunders, Vicky Tsipouri, Gregory J Keir, et al.
American Journal of Respiratory and Critical Care Medicine|August 29, 2020
BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE StudyPhilip L Molyneaux, Jonathan J Smith, Peter Saunders, et al.
The European Respiratory Journal|July 3, 2025
Development and validation of a predictive 6-minute walk score in patients with Idiopathic Pulmonary FibrosisSteven D Nathan, Jie Gao, Ho Cheol Kim, et al.
The European Respiratory Journal|July 7, 2017
Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosisJoseph Jacob, Brian J Bartholmai, Srinivasan Rajagopalan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 20, 2012
18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trialsThida Win, Tryphon Lambrou, Brian F Hutton, et al.
ERJ Open Research|July 19, 2023
Airway soluble CSF1R predicts progression in patients with idiopathic pulmonary fibrosisJustin M Oldham, Kirk W Johnson, Gesa J Albers, et al.
Trials|March 3, 2022
PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis CoughZhe Wu, Winston Banya, Nazia Chaudhuri, et al.
Respiratory Medicine|July 23, 2013
The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung diseaseAmit S Patel, Richard J Siegert, Gregory J Keir, et al.
Clinical and Experimental Rheumatology|July 1, 2017
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™)Oliver Distler, Kevin K Brown, Jörg H W Distler, et al.
Pageof 40